Results 91 to 100 of about 264,642 (338)

Serum-derived exosomal PD-L1 expression to predict anti-PD-1 response and in patients with non-small cell lung cancer

Scientific Reports, 2021
PD-L1 expression is the most useful predictive biomarker for immunotherapy efficacy on non-small cell lung cancer (NSCLC), and CD8+ tumor-infiltrating lymphocytes (CD8+ TILs) play an essential role in the clinical activity of immunotherapy.
Yoshihisa Shimada, Jun Matsubayashi, Yujin Kudo, Sachio Maehara, Susumu Takeuchi, Masaru Hagiwara, Masatoshi Kakihana, Tatsuo Ohira, Toshitaka Nagao, Norihiko Ikeda   +9 more
doaj   +1 more source

The PD-1/PD-L1 Axis and Virus Infections: A Delicate Balance [PDF]

, 2019
Programmed cell death protein (PD-1) and its ligands play a fundamental role in the evasion of tumor cells from antitumor immunity. Less well appreciated is the fact that the PD-1/PD-L1 axis also regulates antiviral immune responses and is therefore ...
Raftery, Martin J., Schönrich, Günther
core   +1 more source

Indoleamine 2,3‐dioxygenase 1 inhibition reverses cancer‐associated fibroblast‐mediated immunosuppression in high‐grade serous ovarian cancer

FEBS Open Bio, EarlyView.
CAF‐mediated immunosuppression in ovarian cancer is driven by IDO1, reducing T‐cell function. Inhibiting IDO1 restores T‐cell proliferation and cytotoxicity, increases cancer cell apoptosis, and may help overcome CAF‐induced immune suppression in high‐grade serous ovarian cancer. Targeting IDO1 may improve antitumor immunity.
Hyewon Lee, Jung Yoon Ho, In Sun Hwang, Youn Jin Choi   +3 more
wiley   +1 more source

Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival : an updated analysis of KEYNOTE-010 trial

, 2019
Background: In KEYNOTE-010, pembrolizumab versus docetaxel improved overall survival (OS) in patients with programmed death-1 protein (PD)-L1-positive advanced non-small-cell lung cancer (NSCLC).
Ahn, M-J, Baas, P, de Castro, G, Jr, Dubos Arvis, C, Emancipator, K, Felip, E, Fidler, MJ, Garon, EB, Garrido, M, Han, J-Y, Herbst, RS, Jensen, EH, Kim, D-W, Kim, J-H, Lubiniecki, GM, Majem, M, Molina, JR, Perez-Gracia, JL, Samkari, A, Shentu, Y, Surmont, Veerle   +20 more
core   +1 more source

Copper‐based Materials for Photo and Electrocatalytic Process: Advancing Renewable Energy and Environmental Applications

Advanced Functional Materials, EarlyView.
Cu‐based catalysts as a cornerstone in advancing sustainable energy technologies are fully reviewed in this manuscript, highlighting their potential in photo‐ and electrocatalysis. It includes metallic copper, copper oxides, copper sulfides, copper halide perovskites, copper‐based metal–organic frameworks (MOFs), and covalent organic frameworks (COFs),
Jéssica C. de Almeida, Yanjie Wang, Thais A. Rodrigues, Paulo H. H. Nunes, Vagner R. de Mendonça, Paulo H. E. Falsetti, Leticia V. Savazi, Tao He, Alexandra V. Bardakova, Aida V. Rudakova, Jie Tian, Alexei V. Emeline, Osmando F. Lopes, Antonio Otavio T. Patrocínio, Jia Hong Pan, Caue Ribeiro, Detlef W. Bahnemann   +16 more
wiley   +1 more source

PD-L1 blockade enhances anti-tumor efficacy of NK cells

OncoImmunology, 2018
Anti-PD-1/anti-PD-L1 therapies have shown success in cancer treatment but responses are limited to ~ 15% of patients with lymphocyte infiltrated, PD-L1 positive tumors.
Jeremiah L. Oyer, Sarah B. Gitto, Deborah A. Altomare, Alicja J. Copik   +3 more
doaj   +1 more source

Clinical and Recent Patents Applications of PD-1/PD-L1 Targeting Immunotherapy in Cancer Treatment—Current Progress, Strategy, and Future Perspective

Frontiers in Immunology, 2020
Targeting PD-L1 and PD-1 interactions is a relatively new therapeutic strategy used to treat cancer. Inhibitors of PD-1/PD-L1 include peptides, small molecule chemical compounds, and antibodies.
Libin Guo, Ran Wei, Yao Lin, Hang Fai Kwok   +3 more
doaj   +1 more source

Regulation of PD-L1 expression in the tumor microenvironment

Journal of Hematology & Oncology, 2021
Programmed death-ligand 1 (PD-L1) on cancer cells engages with programmed cell death-1 (PD-1) on immune cells, contributing to cancer immune escape. For multiple cancer types, the PD-1/PD-L1 axis is the major speed-limiting step of the anti-cancer immune
Ming Yi, Mengke Niu, Linping Xu, Suxia Luo, Kongming Wu   +4 more
doaj   +1 more source

Basis of PD1/PD-L1 Therapies [PDF]

Journal of Clinical Medicine, 2019
It is obvious that tumor cells have developed a number of strategies to escape immune surveillance including an altered expression of various immune checkpoints, such as the programmed death-1 receptor (PD-1) and its ligands PD-L1 and PD-L2. The interaction between PD-1 and PD-L1 results in an activation of self-tolerance pathways in both immune cells ...
openaire   +3 more sources

Endocytic Programming via Porous Silicon Nanoparticles Enhances TLR4 Nanoagonist Potency for Macrophage‐Mediated Immunotherapy

Advanced Functional Materials, EarlyView.
Porous silicon nanoparticles (PSiNPs) reprogram macrophage endocytosis of manganese@albumin‐based TLR4 nanoagonists, driving TRIF‐biased TLR4 signaling, eliciting robust proinflammatory responses, and potentiating macrophage‐mediated immunotherapeutic effects against NSCLC.
Xiaomei Zhang, Huiying Li, Shuodan Huang, Linxuan Zhang, Yan Gao, Ruoran Wang, Xiaoyu Wang, Hélder A. Santos, Zhenyu Yin, Bing Xia   +9 more
wiley   +1 more source